Genexine to conduct Phase Ib/II combination trial of cervical cancer drug GX-188E

Biotechnology firm Genexine has secured approval from the South Korean Ministry of Food and Drug Safety (MFDS) to conduct a Phase Ib/II trial of GX-188E vaccine in combination with Keytruda (pembrolizumab) in patients with non-resectable cervical can …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news